Anebulo Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Contents
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject the “safe harbor” created by those sections. These forward-looking statements about us and our industry involve substantial risks and uncertainties and our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, “Risk Factors” in this Quarterly Report and the “Risk Factors” as set forth in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024 filed with the Securities and Exchange Commission (the “SEC”) on September 25, 2024 (the “2024 Form 10-K”). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “seek,” “plan,” “expect,” “should,” “would,” “potentially” or the negative of these terms or similar expressions in this Quarterly Report.
We have based these forward-looking statements largely on our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These forward-looking statements include, but are not limited to, statements about:
| ● | our expectations regarding our capital requirements, expenses and other operating results, and needs for additional financing; |
| ● | the timing or outcome of any of our regulatory submissions; |
| ● | the timing and conduct of our clinical trials, including statements regarding the timing, progress and results of current and future nonclinical studies and clinical trials, and our research and development programs; |
| ● | the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of selonabant (formerly ANEB-001) |
| ● | our expectations regarding future growth; |
| ● | our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; |
| ● | our ability to maintain our existing licensing arrangements and enter into and maintain other collaborations or licensing arrangements; |
| ● | our estimates regarding the commercial potential and market opportunity for our product candidates; |
| ● | the performance of our third-party suppliers and manufacturers; |
| ● | our ability to compete effectively with existing competitors and new market entrants; |
| ● | the impact on our business of economic or political events or trends; and |
| ● | the impact of governmental laws and regulations. |
You should not place undue reliance on these forward-looking statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully read this Quarterly Report, including the section titled “Risk Factors” and the documents that we reference in this Quarterly Report and have filed as exhibits to this Quarterly Report as well as the 2024 Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this report by these cautionary statements.
PART I. FINANCIAL INFORMATION
Condensed Balance Sheets
| September 30, 2024 | June 30, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,404,211 | $3,094,200 |
| Grant receivable | 245,362 | - |
| Prepaid expenses | 312,940 | 413,790 |
| Total current assets | $1,962,513 | $3,507,990 |
| Other assets: | ||
| Loan commitment fees | 505,427 | 565,124 |
| Total assets | 2,467,940 | 4,073,114 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $252,142 | $156,426 |
| Accrued expenses | 317,083 | 104,157 |
| Total liabilities | 569,225 | 260,583 |
| Commitments and contingencies | - | - |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 2,000,000 shares authorized, no shares issued or outstanding at September 30, 2024 and June 30, 2024 | - | - |
| Common stock, $0.001 par value; 50,000,000 authorized at September 30, 2024 and June 30, 2024; 25,933,217 shares issued and outstanding at September 30, 2024 and June 30, 2024 | 25,934 | 25,934 |
| Additional paid-in capital | 69,477,261 | 69,190,341 |
| Accumulated deficit | (67,604,480) | (65,403,744) |
| Total stockholders’ equity | 1,898,715 | 3,812,531 |
| Total liabilities and stockholders’ equity | $2,467,940 | $4,073,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.